✦ LIBER ✦

Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma

✍ Scribed by Madan, Sumit; Dispenzieri, Angela; Lacy, Martha Q.; Buadi, Francis; Hayman, Suzanne R.; Zeldenrust, Steven R.; Rajkumar, S. Vincent; Gertz, Morie A.; Kumar, Shaji K.

Book ID: 123583722
Publisher: Mayo Clinic
Year: 2010
Tongue: English
Weight: 139 KB
Volume: 85
Category: Article
ISSN: 0025-6196
DOI: 10.4065/mcp.2009.0547

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Asymptomatic immunoglobulin light chain

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

✍ Sergio Siragusa; William Morice; Morie A. Gertz; Robert A. Kyle; Philip R. Greip 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 113 KB

Bortezomib Subcutaneous Injection in Com

Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients

✍ Shah, Gunjan; Kaul, Esha; Fallo, Shelly; Cossor, Furha; Smith, Hedy; Sprague, Ke 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Bendamustine and prednisone in combinati

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

✍ Pönisch, Wolfram; Moll, Barbara; Bourgeois, Malvina; Andrea, Marc; Schliwa, Thom 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 336 KB

Bortezomib Induction and Maintenance Tre

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

✍ Sonneveld, P.; Schmidt-Wolf, I. G. H.; van der Holt, B.; el Jarari, L.; Bertsch, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 232 KB

Prognostic significance of the S-phase f

Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

✍ Trendle, M.C.; Leong, T.; Kyle, R.A.; Katzmann, J.A.; Oken, M.M.; Kay, N.E.; Van 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the pr

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB